All manuscripts
Publications TIL Cells G-Rex®100

Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation

Published Journal Journal for ImmunoTherapy of Cancer

Share
No image preview

Overview

The study identifies SIK3 as a gene protecting tumor cells from T-cell cytotoxicity. In the methods, TILs were rapidly expanded using a modified Rosenberg protocol involving culture in G-Rex® 100 with feeder cells and IL-2.

What this paper found

Tumor cells use salt-inducible kinase 3 (SIK3) to resist killing by cytotoxic T cells, because SIK3 sustains TNF-driven NF-κB signaling and pro-survival gene expression. An siRNA screen of 2887 genes in PANC-1 pancreatic cancer cells cocultured with patient-derived TILs, confirmed with survivin-specific T-cell clones, identified 108 candidate genes, with SIK3 among the strongest hits. Genetic or drug-based SIK3 inhibition increased T-cell killing of pancreatic, breast, colorectal and melanoma cells, and in NSG mice, SIK3-deficient melanoma tumors grew more slowly after TIL transfer. Neutralizing TNF fully rescued SIK3-depleted cells from T-cell-induced death. In 178 TCGA pancreatic cancer patients, a low TNF/SIK3/NF-κB signature index was linked to longer survival (p=0.0012), with more than 75% of low-index patients alive after 7 years.

Note: Preclinical study in cell lines, patient-derived TILs and a mouse xenograft model; the authors note that SIK3 is also expressed in many healthy tissues, so systemic SIK3 blockade could cause adverse effects.

In this work, we show for the first time that tumor cells exploit SIK3 to counteract TC attack by promoting prosurvival gene expression after TNF stimulation. — Antonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, Valentina Volpin, Franziska Christine Durst, Julian Sax, Maria Xydia, Abir Hussein, Slava Stamova, Steffen Spoerl, Nicole Heuschneider, Jasmin Muehlbauer, Katharina Marlene Jeltsch, Anchana Rathinasamy, Melanie Werner-Klein, Marco Breinig, Damian Mikietyn, Christian Kohler, Isabel Poschke, Sabrina Purr, Olivia Reidell, Catarina Martins Freire, Rienk Offringa, Claudia Gebhard, Rainer Spang, Michael Rehli, Michael Boutros, Christian Schmidl, Nisit Khandelwal, Philipp Beckhove, Journal for ImmunoTherapy of Cancer

Study details

Authors
Antonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, Valentina Volpin, Franziska Christine Durst, Julian Sax, Maria Xydia, Abir Hussein, Slava Stamova, Steffen Spoerl, Nicole Heuschneider, Jasmin Muehlbauer, Katharina Marlene Jeltsch, Anchana Rathinasamy, Melanie Werner-Klein, Marco Breinig, Damian Mikietyn, Christian Kohler, Isabel Poschke, Sabrina Purr, Olivia Reidell, Catarina Martins Freire, Rienk Offringa, Claudia Gebhard, Rainer Spang, Michael Rehli, Michael Boutros, Christian Schmidl, Nisit Khandelwal, Philipp Beckhove
Institution
Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany · Translational Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany · Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany · Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany · Signalling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany · Helmholtz-University Group ‘Cell Plasticity and Epigenetic Remodeling’, German Cancer Research Center (DKFZ), Heidelberg, Germany · Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany · Institute of Functional Genomics, University of Regensburg, Regensburg, Germany · Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ), Heidelberg, Germany · DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany · Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany · Joint Immunotherapeutics Laboratory, German Cancer Research Center (DKFZ), Heidelberg, Germany · Research Department, iOmx Therapeutics, Munich/Martinsried, Germany · Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany · Functional Genomics, University of Regensburg, Regensburg, Germany · Junior Group 'Epigenetic Immunooncology', Leibniz Institute for Immunotherapy, Regensburg, Germany
Journal
Journal for ImmunoTherapy of Cancer
Year
2022
PMID / PMC
PMID: 35606086 · PMC
G-Rex® model(s)
G-Rex®100
Cell type(s)
TIL Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

Melanoma- and pancreatic cancer-derived TILs were rapidly expanded with a modified Rosenberg protocol in a G-Rex® 100 cell culture flask. TILs were cocultured with irradiated feeder cells at a 1:100 ratio (for example, 2 × 10^6 TILs with 200 × 10^6 feeders) in 400 mL of expansion medium with 30 ng/mL OKT3 and 3000 IU/mL IL-2 for 5 days without moving. After a partial medium exchange, the cells were split into three G-Rex® 100 flasks on day 7, fed again on day 11, and collected and counted on day 14.

Explore related

Full citation

Sorrentino A, Menevse AN, Michels T, et al. Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. J Immunother Cancer. 2022;10(5):e004258.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →